Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.31 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.31 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23827914 | 0.90 | POLRMT (0.70) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL16699074 | 0.83 | POLRMT (0.71) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL16699077 | 0.83 | POLRMT (0.71) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL20960037 | 0.79 | POLRMT (0.79) | POLRMT | |
| SCHEMBL23844015 | 0.79 | POLRMT (0.48) | POLRMT | |
| SCHEMBL20960039 | 0.78 | POLRMT (0.49) | POLRMT | |
| SCHEMBL20756290 | 0.77 | POLRMT (0.73) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL23844007 | 0.77 | POLRMT (0.44) | POLRMTSTING1 | |
| SCHEMBL23827983 | 0.77 | POLRMT (0.47) | POLRMTSTING1 | |
| SCHEMBL20755989 | 0.77 | POLRMT (0.72) | POLRMTP2RY1P2RY2P2RY11P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | POLRMT 76/4885P2RY1 497/4885P2RY2 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.